TY - JOUR
T1 - Coronary Atherosclerotic Plaque Regression
T2 - JACC State-of-the-Art Review
AU - Dawson, Luke P.
AU - Lum, Mark
AU - Nerleker, Nitesh
AU - Nicholls, Stephen J.
AU - Layland, Jamie
N1 - Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/1/4
Y1 - 2022/1/4
N2 - Over the last 3 decades there have been substantial improvements in treatments aimed at reducing cardiovascular (CV) events. As these treatments have been developed, there have been parallel improvements in coronary imaging modalities that can assess plaque volumes and composition, using both invasive and noninvasive techniques. Plaque progression can be seen to precede CV events, and therefore, many studies have longitudinally assessed changes in plaque characteristics in response to various treatments, aiming to demonstrate plaque regression and improvements in high-risk features, with the rationale being that this will reduce CV events. In the past, decisions surrounding treatments for atherosclerosis have been informed by population-based risk scores for initiation in primary prevention and low-density lipoprotein cholesterol levels for titration in secondary prevention. If outcome data linking plaque regression to reduced CV events emerge, it may become possible to directly image plaque treatment response to guide management decisions.
AB - Over the last 3 decades there have been substantial improvements in treatments aimed at reducing cardiovascular (CV) events. As these treatments have been developed, there have been parallel improvements in coronary imaging modalities that can assess plaque volumes and composition, using both invasive and noninvasive techniques. Plaque progression can be seen to precede CV events, and therefore, many studies have longitudinally assessed changes in plaque characteristics in response to various treatments, aiming to demonstrate plaque regression and improvements in high-risk features, with the rationale being that this will reduce CV events. In the past, decisions surrounding treatments for atherosclerosis have been informed by population-based risk scores for initiation in primary prevention and low-density lipoprotein cholesterol levels for titration in secondary prevention. If outcome data linking plaque regression to reduced CV events emerge, it may become possible to directly image plaque treatment response to guide management decisions.
KW - atherosclerotic plaque
KW - coronary artery disease
KW - imaging
KW - ischemic heart disease
KW - plaque modification
UR - http://www.scopus.com/inward/record.url?scp=85121616124&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.10.035
DO - 10.1016/j.jacc.2021.10.035
M3 - Review Article
C2 - 34991791
AN - SCOPUS:85121616124
SN - 0735-1097
VL - 79
SP - 66
EP - 82
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -